Drugs / Emraclidine
Emraclidine
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 114 trials | ||||||
| Phase 1 | NCT07587008 | May → Jul 2026 overdue | — | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07219030 | Oct 2025 → Dec 2026 expected | — | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT06366243 | May → Jun 2024 | — | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT06301971 | Mar → Apr 2024 | — | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05965219 | Aug → Nov 2023 | — | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05940402 | Jul 2023 → Dec 2024 | impaired renal function disease | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05933187 | Jul → Sep 2023 | — | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05935033 | Jun 2023 → Feb 2025 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05915546 | Jun → Jul 2023 | — | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05644977 | Dec 2022 → Apr 2025 | Alzheimer disease | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05245539 | Jan → Oct 2022 | hypertensive disorder, schizophrenia | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05106309 | Dec 2021 → Feb 2022 | schizophrenia | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04787302 | Jun 2021 → Jul 2023 | schizophrenia | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03217604 | Jul 2017 → Feb 2018 | — | Pfizer | Completed | No outcome recorded |
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT07145918 | Aug 2025 → Feb 2028 expected | schizophrenia | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT05443724 | Sep 2022 → Jun 2025 | schizophrenia | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT05227703 | Jul 2022 → Aug 2024 | schizophrenia | AbbVie | Completed | Missed primary |
| Phase 2 | NCT05227690 | Jun 2022 → Aug 2024 | schizophrenia | AbbVie | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04136873 Comparator | Oct 2019 → May 2021 | schizophrenia | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2024-11-11 | AbbVie | Results AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia abbvie.com ↗
EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint |
| 2022-12-19 | AbbVie | Results Cerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring Trial abbvie.com ↗
On the primary endpoint, emraclidine demonstrated a mean change from baseline at week eight in 24-hour ambulatory systolic blood pressure (SBP) of -2.7 mmHg for the 10 mg QD group and -0.4 mmHg for the 30 mg QD group. |
| 2022-12-15 | AbbVie | Results Cerevel Therapeutics Announces Publication in The Lancet of Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia abbvie.com ↗
Data show clinically meaningful and statistically significant improvement with emraclidine in PANSS total score at six weeks and was overall well-tolerated compared with placebo |
| 2022-11-08 | AbbVie | Regulatory Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates abbvie.com ↗
Received FDA Fast Track designation for emraclidine in Alzheimer’s disease psychosis |
| 2021-06-29 | AbbVie | Results Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia abbvie.com ↗
Importantly, both the 30 mg once-daily and the 20 mg twice-daily doses demonstrated clinically meaningful antipsychotic activity with an overall well-tolerated profile compared with placebo. |
All press releases naming this drug 8 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emraclidine | “CVL-231 (Emraclidine)” NCT05443724 ↗ |
| Known as | 1-(2,4-DIMETHYL-5,7-DIHYDRO-6H-PYRROLO[3,4-B]PYRIDIN-6-YL)-2-{1-[2-(TRIFLUOROMETHYL)PYRIDIN-4-YL]AZETIDIN-3-YL}ETHANONE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314557 ↗ |
| Known as | CVL-231 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04787302 ↗ |
| Known as | PF-06852231 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03217604 ↗ |
| Action | Activate | “positive allosteric modulator” PMID 36528376 ↗ Dec 2022 |
| Modality | Small molecule | — CHEMBL5314557 ↗ |
| Route | Oral | “Single Ascending Oral Doses Of Pf-06852231 Administered To Healthy Adult Subjects” NCT03217604 ↗ |